Background: Bevacizumab is an antiangiogenic agent active in patients with recurrent malignant gliomas. However, evidence for its clinical efficacy is relatively limited so that bevacizumab is approved for this indication in Canada and the United States, but not in the European Union. We reviewed the effectiveness of bevacizumab in patients with recurrent brain tumour using a large population database. Methods: This was a retrospective, multicentre, study conducted at the BC Cancer Agency, a public cancer care organisation for the residents of the Canadian province of British Columbia. Cases were identified from the provincial registry and drug database. Patients were eligible if they were treated with bevacizumab with or without lomustine or etoposide for recurrent brain tumour between April 2011 and March 2014. The primary end points were progressionfree survival. Secondary endpoints were overall survival and objective response rate. Results: A total of 160 patients were included, with a median age of 55 years. The most common diagnosis was glioblastoma multiforme (70.6%), followed by oligodendroglioma (10.6%). Half of the patients had prior metronomic dosing of temozolomide. The median duration of therapy was 3 months. The median progression-free survival was 4.0 months and the 6-month progression-free survival was 29.4%. The median overall survival was 7 months and the 9-month and 12-month overall survival was 28.1% and 20.6%, respectively. The objective response rate was 23.1%. The most common documented reason for bevacizumab discontinuation was disease progression (66.9%), followed by toxicity (6.9%). Conclusions: Bevacizumab therapy seems to be effective in delaying disease progression in patients with recurrent brain tumour, but with limited benefits on the overall survival, when used outside the clinical trial setting.
Introduction
Bevacizumab is an antiangiogenic agent targeted at the vascular endothelial growth factor (VEGF) receptor involved in the abnormal vasculature seen in malignant gliomas. In one phase II study of 85 patients with first or second relapse after radiotherapy and temozolomide, bevacizumab was associated with a median overall survival (OS) of 9.2 months, progression-free survival (PFS) of 4.2 months, objective response (OR) rate of 28.2%, 6-month PFS of 42.6% and 12-month OS of 23.2%. 1 Based on these data, bevacizumab has been approved for this indication by Health Canada and the FDA. However, the European Medicines Agency did not approve this indication, citing the limitation of phase II data and the feasibility of conducting a phase III trial. 2 In the Canadian province of British Columbia, bevacizumab with or without lomustine or oral etoposide has been funded for relapsed high grade 1 Provincial Pharmacy, Systemic Therapy Program, BC Cancer Agency, Victoria, BC, Canada 2 At the time of the study, Provincial Pharmacy Professional Practice Council, BC Cancer Agency, Victoria, BC, Canada malignant glioma since April 2011. In contrast, the province of Ontario has reiterated its decision of not funding bevacizumab for this indication, after reviewing new clinical evidence in the relapsed 3 and first-line setting. 4, 5 Bevacizumab is a costly therapy and the cost-effectiveness of this treatment remains uncertain for this indication. Given the limited supporting evidence and the inconsistent regulatory approval and provincial funding, we reviewed the clinical outcomes of the patients in British Columbia treated with bevacizumab for recurrent brain tumour.
Methods

Study design and patient population
This was a retrospective, multicentre study to evaluate the effectiveness of bevacizuamb alone or with lomustine or oral etoposide in adult patients with recurrent brain tumours after standard therapy (e.g. metronomic dosing of temozomide). Patients were identified through the provincial cancer registry and systemic therapy drug database of the BC Cancer Agency. Inclusion criteria included: Exclusion criteria included previous treatment of bevacizumab at private infusion clinics or as part of clinical trials, since there was limited access to medical documentation of these patients. In addition, their inclusion would have introduced selection bias because they would have been identified only if they had requested subsequent funding from the BC Cancer Agency. Hence, they would present only the responding patients. Data were collected based on documentation in the provincial cancer registry system and the systemic therapy drug database. ECOG status was the score documented within 1 month of the first dose of bevacizumab. Ethics approval was obtained from the BC Cancer Agency Research Ethics Board for the collection, analysis and presentation of these data.
Assessment of efficacy
The primary endpoints were the PFS and the PFS rate at 6 months. The secondary endpoints were the OS, the OS at 12 months and the clinical overall response rate. Progress notes of all patients were reviewed until discontinuation of bevacizumab, lost to follow-up, censored date (4 September 2015), or death. Patients lost to follow-up were censored at the date they were last known to be alive. Disease progression and response were assessed using criteria adopted from the NeuroOncology Working Group response assessment for high-grade gliomas 6 (Appendix). Date of response was the date of MRI report and, if not available, the date of the clinical notes reporting the radiological response. Overall response rate was defined as a complete or partial response.
Data analysis
Statistical analyses were performed in all patients who had at least one dose of bevacizumab. Kaplan-Meir method was used to estimate the median PFS, 6-month PFS, median OS and 12-month OS. Clinical significance was defined as 6-month PFS 40% and OR rate 25%, based on the 6-month PFS of 42.6% and OR rate 28.3% reported by Friedman et al. 1 Clinical outcomes were compared to those reported in clinical trials and population analysis.
Results
A total of 160 eligible patients were identified. Table 1 presents the baseline demographics of the patients. No ECOG status was documented in 45.6% of the patients within 1 month of the initiation of bevacizumab treatment. Glioblastoma multiforme was the most common diagnosis. Fifty percent of the patients had previously been treated with metronomic (continuous) dosing of temozolomide. 7 The median time from initial diagnosis and last radiotherapy to bevacizumab treatment was 13 months and 11 months, respectively. Thirty percent of the patients had received one line of prior therapy, with 55% having two lines of prior therapies. The median duration of follow-up was 7 months and the median duration of bevacizumab therapy was 3 months. The most common reasons for bevacizumab discontinuation were disease progression (66.9%), with only 6.9% of patients stopping therapy due to reported toxicity.
Clinical outcomes
One hundred and fifty-two patients (95.0%) had either disease progression or died. The median PFS was 4.0 months and the estimated 6-month PFS rate was 29.4%. One hundred and forty-nine patients (93.1%) had died at the last follow-up. The median OS time from initiation of bevacizumab therapy was 7.0 months. The estimated 9-month and 12-month OS rates were 28.1% and 20.6%, respectively. No patient had a documented complete response and 37 patients (23.1%) had a partial response, making the OR rate of 23.1%. Fifty patients (31.3%) had documented stable disease.
Discussion
Our findings suggest that the effectiveness of bevacizumab in patients with recurrent brain tumour in real world clinical settings seems to be largely comparable to the efficacy reported in clinical trials (Table 2) . Notwithstanding the limitations of cross-trial comparison and the population-based data of our analysis, our study showed a similar median PFS but slightly lower 6-month PFS compared to those reported in the pivotal trial by Friedman et al. 1 and the recent BELOB study. 3 It should be noted, however, that there was no blinding of assessment in our study. The overall survival benefit was more limited compared to the clinical trials, with shorter median OS 1,3 and lower 12-month OS rate. 3 Similarly, the OR was slightly lower than those reported in the clinical trials. Overall, bevacizumab therapy appears to be effective in delaying disease progression in patients and generally well tolerated. However, the effect on disease progression did not seem to be translated into significantly prolonging the overall survival of these patients. Bevacizuamb is a reasonable option for patients with recurrent brain tumors and who have failed or cannot tolerate standard therapy (e.g. temozolomide, nitrosoureas) or experience symptoms associated with cerebral edema requiring high doses of corticosteroids.
Conclusions
Bevacizumab therapy seems to be effective in delaying disease progression in patients with recurrent brain tumour, but with limited benefits on the overall survival, when used outside the clinical trial setting.
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